Reseach

centers and institutes

1997.12 Shandong Provincial Key Laboratory of Natural Medicines

1999.11 Shandong Provincial Drug Preclinical Research Center

2001.12 Ministry of Health Key Laboratory of Biotechnology Drugs

2009.01 National Major New Drug Development - Shandong Major New Drug Development Platform - Pharmacology Evaluation Unit Technical Platform

2010.01 National Shandong Innovative Drug Incubation Base - Biopharmaceutical Preclinical Evaluation Technical Platform

2012.12 Shandong Provincial Drug Release Engineering Technology Research Center

2015.01 National Technology Transfer Demonstration Institution

2015.11 National Certified Drug Evaluation GLP Laboratory

2018.10 Shandong Provincial Innovation Public Service Platform - Innovative Drug Development and Evaluation Service Platform

2019.01 Shandong Provincial Collaborative Innovation Center for Key Technologies and Industrialization of Innovative Drug Development

2019.04 Shandong Provincial New Technology Pharmaceutical Engineering Laboratory

2023.04 National Key Laboratory for Advanced Drug Delivery Systems


Representatives

Achievements Review:


1 Second Prize of National Science and Technology Progress Award

17 New Drug Certificates

2 Projects under the National "863" Program

5 Projects under the National Major Science and Technology Special Project for the Creation of Major New Drugs (including sub-projects)

3 Projects approved for funding exceeding tens of millions of yuan under the Shandong Province "Major Science and Technology Special Project for Independent Innovation"


Representative Achievements:

Tijiao Capsule (awarded the National Science and Technology Progress Second Prize) Transferred to Shandong New Era Pharmaceutical Co., Ltd. Launched in 2008, with sales exceeding 100 million yuan, and sales exceeding 1.2 billion yuan in the first three years after listing Currently, the company's annual sales exceed 2 billion yuan, with a market share of over 75%

Platinum-based series of anticancer drugs (the earliest in China)

Broad-spectrum first-line anticancer drugs

Cisplatin, Carboplatin, Oxaliplatin were all first launched in the market

Currently still the main products of Qilu Pharmaceutical, Dezhou Pharmaceutical, and Dalian

3. Ge Gen Su and Formulations (original research laboratory)

Transferred to Yantai Luyin Pharmaceutical Co., Ltd. (trade name Pulelin)

There are currently 218 approval numbers in the market, produced by 120 companies

The market size exceeds 100 billion

4. Injectable Esomeprazole Sodium (Market Transformation from Basic Research)

Developed jointly with Dezhou Deyao Pharmaceutical Co., Ltd.

Approved for market in 2019

Potential economic benefits exceed 7 billion yuan



Baidu
map